67 enrolling by invitation. 67 Phase 2, 18 Phase 1, 5 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 67 | Enrolling by invitation 67 |
| Phase 1 | 18 | Enrolling by invitation 18 |
| Phase 3 | 5 | Enrolling by invitation 5 |
Follow Nervous System Diseases: new trials by email Literature Review of Nervous System Diseases trials Research Report on Nervous System Diseases
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Antisense Oligonucleotide Therapy for a Participant With TARDBP ALS nL-TARDB-002 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 1 | 2026-12-01 | 2026-07-14 |
| Alzheimer's Tau Platform: Regimen A - AADvac1 AADvac1, Donanemab - Preclinical Alzheimer's Disease, Prodromal Alzheimer's Disease | Phase 2 | Enrolling by invitation | Paul S. Aisen | 450 | 2026-11-03 | 2026-10-26 |
| Open-Label Access to ATH434 for Patients Who Completed Study ATH434-201 in France ATH434 - Multiple System Atrophy | Phase 2 | Enrolling by invitation | Alterity Therapeutics | 7 | 2026-10-01 | 2026-10-09 |
| The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab Foralumab Nasal, Placebo - ALS (Amyotrophic Lateral Sclerosis), ALS - Amyotrophic Lateral Sclerosis | Phase 2 | Enrolling by invitation | Tiziana Life Sciences LTD | 44 | 2026-09-23 | 2026-10-28 |
| Safety, Dose-Finding, and Efficacy of Transcranial Pulse Stimulation for Post-Stroke Neurorehabilitation Required Field - Ischemic Stroke | Phase 1 / Phase 2 | Enrolling by invitation | Taipei Hospital, Ministry of Health and Welfare | 9 | 2026-08-20 | 2026-08-25 |
| Alzheimer's Disease Research Center (ADRC) PET Component Study 18F-MK6240, 18F-Florbetaben (FBB) - Alzheimer Disease, Mild Cognitive Impairment (MCI) | Phase 2 | Enrolling by invitation | Patrick Lao | 120 | 2026-08-06 | 2026-08-11 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen A: AADvac1 AADvac1, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 146 | 2026-07-29 | 2026-11-05 |
| The Progressive Supranuclear Palsy Clinical Trial Platform - Regimen B: LM11A-31 LM11A-31, Matching Placebo - PSP - Progressive Supranuclear Palsy | Phase 2 | Enrolling by invitation | Adam Boxer | 147 | 2026-07-29 | 2026-11-05 |
| TRACK-TBI Precision Medicine Part 3 - Option II Cyclosporine (CsA), Placebo - Traumatic Brain Injury | Phase 2 | Enrolling by invitation | University of California, San Francisco | 26 | 2026-07-02 | 2026-10-22 |
| DMSO Dual-Route Therapy for Refractory Tinnitus in Long-COVID and Post-COVID-19 Vaccine Injury DMSO-based otic solution with betahistine, dexamethasone, and lidocaine, DMSO-based transdermal cream with levocarnitine and N-acetylcysteine - Tinnitus | Phase 2 | Enrolling by invitation | Leading Edge Clinic | 20 | 2026-05-15 | 2026-05-13 |
| Autism Spectrum Disorder (ASD) Neurodevelopmental Disorder With Issues Social Behavior, Communication Issues, GI Dysfunction. Study is Multimodal Interventions Targeting These Pathways With cSVF, Stored MSCs, FMT and Diet Modification. Role of Autoimmunity, Gut-brain Issues, & Issues Examined. Autologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol - Autism Spectrum Disorder, Autism | Phase 1 / Phase 2 | Enrolling by invitation | Black Tie Medical, Inc. | 50 | 2026-04-30 | 2026-04-27 |
| An Open-Label Extension Study to Evaluate the Long-term Safety and Efficacy of BMN 351 in Participants With Duchenne Muscular Dystrophy BMN 351 - Duchenne Muscular Dystrophy (DMD) | Phase 2 | Enrolling by invitation | BioMarin Pharmaceutical | 18 | 2026-04-20 | 2026-07-24 |
| An Extension of SKY-0515 in Participants With Huntington's Disease SKY-0515 - Huntington's Disease (HD) | Phase 2 / Phase 3 | Enrolling by invitation | Skyhawk Therapeutics, Inc. | 500 | 2026-04-10 | 2026-07-24 |
| An Open-Label Study of ML-007C-MA in Adults With Alzheimer's Disease Psychosis ML-007C-MA - Psychosis Associated With Alzheimer's Disease | Phase 2 | Enrolling by invitation | MapLight Therapeutics | 210 | 2026-03-25 | 2026-08-07 |
| Personalized Antisense Oligonucleotide Therapy for Participants With TARDBP ALS nL-TARDB-006 - Amyotrophic Lateral Sclerosis (ALS) | Phase 1 / Phase 2 | Enrolling by invitation | n-Lorem Foundation | 6 | 2026-02-19 | 2026-08-03 |
| Effect of Melatonin on Oxidative Stress Parameters in Levodopa-Treated Parkinson's Disease Patients MELATONIN (MELATL07959) - Parkinson Disease | Phase 2 | Enrolling by invitation | Bangladesh Medical University | 70 | 2026-02-17 | 2026-01-29 |
| Open-Label Extension Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy WVE-N531 - Duchenne Muscular Dystrophy | Phase 2 | Enrolling by invitation | Wave Life Sciences USA, Inc. | 175 | 2025-12-28 | 2026-03-06 |
| Lamivudine as a Novel Clinical Effort for Rett Syndrome Lamivudine - Rett Syndrome | Phase 2 | Enrolling by invitation | Maria Denise Fernandes Carvalho de Andrade | 10 | 2025-11-05 | 2026-06-10 |
| Tau PET Outcomes With Anti-amyloid Immunotherapies 18F-AV-1451, C-11 ER-176 - Cognitive Impairment, Mild, Dementia, Mild | Phase 2 | Enrolling by invitation | Mayo Clinic | 135 | 2025-11-04 | 2026-10-30 |
| Electromagnetic Immunotherapy Mapping and Cytokine Forecasting Study (QSIT) Low-Frequency Electromagnetic Resonance Therapy (LF-EMR), Sham Resonance Device (Inactive Control), Low-Dose Naltrexone (LDN) - Systemic Lupus Erythematosus, Rheumatoid Arthritis | Phase 1 / Phase 2 | Enrolling by invitation | Truway Health, Inc. | 120 | 2025-10-23 | 2026-05-22 |
Showing 20 of 67. Sign in to see all of them.
Alzheimer Disease (7) · Amyotrophic Lateral Sclerosis (4) · Brain Injuries, Traumatic (4) · Cognitive Dysfunction (4) · Dementia (4) · Ischemic Stroke (4) · Muscular Dystrophy, Duchenne (4) · Multiple Sclerosis (3) · Neuroinflammatory Diseases (3) · Agnosia (2) · Arthritis, Rheumatoid (2) · Autoimmune Diseases (2) · Epilepsies, Partial (2) · Epilepsy (2) · Frontotemporal Dementia (2)
Central Nervous System Diseases (37) · Brain Diseases (32) · Neurodegenerative Diseases (21) · Neuromuscular Diseases (18) · Pathological Conditions, Signs and Symptoms (18) · Neurologic Manifestations (15) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (14) · Genetic Diseases, Inborn (13) · Mental Disorders (13) · Metabolic Diseases (13) · Nutritional and Metabolic Diseases (13) · Signs and Symptoms (13) · Musculoskeletal Diseases (12) · Neurocognitive Disorders (10)
Dexmedetomidine (3) · AADvac1 (2) · Atorvastatin (2) · Fecal Microbiota Transplantation (2) · Saline Solution (2) · 2-(4'-(methylamino)phenyl)-6-hydroxybenzothiazole (1) · 4-(N-methylamino)-4'-(2-(2-(2-fluoroethoxy)ethoxy)ethoxy)stilbene (1) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (1) · 8-hydroxyquinazolin-4(3H)-one (1) · ATH434 (1) · Acetylcysteine (1) · Acupuncture Therapy (1) · Anti-Inflammatory Agents (1) · Betahistine (1) · Blood Specimen Collection (1)
Mayo Clinic (4) · n-Lorem Foundation (3) · Adam Boxer (2) · Sarepta Therapeutics, Inc. (2) · University of California, San Francisco (2) · Akiva Mintz (1) · Alterity Therapeutics (1) · Amr Mohamed Sedik (1) · Bangladesh Medical University (1) · Beijing Chest Hospital (1) · BioMarin Pharmaceutical (1) · Biohaven Therapeutics Ltd. (1) · Black Tie Medical, Inc. (1) · Brigham and Women's Hospital (1) · Capital Medical University (1)
United States (45) · Australia (9) · United Kingdom (9) · Netherlands (8) · Spain (8) · France (7) · Germany (7) · Belgium (6) · Canada (6) · Italy (6) · Israel (4) · New Zealand (4) · Poland (3) · Argentina (2) · Brazil (2)
Adam Boxer, MD, PhD (3) · Anne-Marie Wills, MD (2) · Irene Litvan, MD (2) · Julio Rojas-Martinez, MD, PhD (2) · Alejandra Gonzalez-Duarte, MD (1) · Amir Minerbi, MD-PhD (1) · Amy A Herrold, PhD BA (1) · Aravind Ganesh, MD, DPhil (1) · Avindra Nath, M.D. (1) · Burcu Zeydan, MD (1) · Emily B. Martin, PhD (1) · Farzana Akter, MBBS (1) · Gavin Solomon, President & CEO (1)
PMID 34057284, PMID 35947827, PMID 40550124, PMID 40957959, PMID 41813043, PMID 42176392
2023 (4), 2025 (2), R01AG085029 (2), I01RX002916 (1), P01NS044233 (1), P30AG066462 (1), P50AG016574 (1), R01AG050440 (1), R01AG055299 (1), R01AG078457 (1), R33AG084477 (1), RF1AG051556 (1)